



| Catalog No. | HF974016 |
|---|---|
| Description |
Apolizumab (HF974016) is a research-grade recombinant antibody targeting HLA class II histocompatibility antigen. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Species reactivity | Human |
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
| Host species | Humanized |
| Isotype | IgG1-nd |
| Expression system | Mammalian Cells |
| Clonality | Monoclonal |
| Target | HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA-DRB1 |
| Endotoxin level | Please contact the lab for this information. |
| Purity | >95% purity as determined by SDS-PAGE. |
| Purification | Protein A/G purified from cell culture supernatant. |
| Accession | P01911 |
| Form | Liquid |
| Storage buffer | 0.01M PBS, pH 7.4. Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA. |
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
| Alternate Names | Hu1D10, 267227-08-7 |
| Background | HLA class II histocompatibility antigen, DRB1 beta chain (HLA-DRB1) is a ~29 kDa protein. A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Schulze zur Wiesch, J. et al. (2005) Journal of immunology (Baltimore, Md. : 1950) 175, 3603-13. PMID: 16148104 3. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 4. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 5. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 6. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 7. Topalian, SL. et al. (1996) The Journal of experimental medicine 183, 1965-71. PMID: 8642306 8. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 9. Schmid, D. et al. (2007) Immunity 26, 79-92. PMID: 17182262 |
| Note | For research use only. Not suitable for clinical or therapeutic use. |

SEC-HPLC detection for Research Grade Apolizumab.

SDS-PAGE for Research Grade Apolizumab




Contact us for custom quotes, bulk requests and any other issues.
Mail: support@abinScience.com




+86-27-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский